Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Dec 13, 2022 10:45am
261 Views
Post# 35168377

Share Value Loss

Share Value LossSpectral was full of opportunity and potential at the time Seto came on board.  The share price was in excess of $0.70 per share.  Paradigm had put a value of $2.00 per share that was revised to over $4.00 per share when the Baxter deal was announced.

Since then the share price has dropped to a pathetic $0.33 per share and today we find out we've lost 70% of the value of Dialco because he permitted and oversaw a non-compliance with the Infomed agreement.  That's the only facts reluctantly provided to shareholders.  Infomed are obviously prudent businessmen and with Swiss efficiency have scored 70% of Dialco for zero dollars.  Forget all the nice words in the press release - we are now a minority partner in our company at 30% after a forced giveaway of 70% and our fortunes with Dialco will be determined by Infomed acting on their own as majority.  A laughing stock to the market.

I don't see any value exhibited by management over the last 3 years.  Only loss of value.  Time to stop doing the same old thing hoping for a different outcome.  Time to sell our assets for the inherent value now before it's dissipated by incompetent management.
<< Previous
Bullboard Posts
Next >>